Ligand Pharmaceuticals Incorporated LGNZZ Company

New Post Public Reply Private Reply Replies (0) Message Board

Sep 3, 2013 at 8:59 PM

Ligand Pharmaceuticals Incorporated LGNZZ Company Overview

Stock Message Board http://investorshangout.com/search?q=LGNZZ&am...mp;yt1=Go!

Ligand Pharmaceuticals Incorporated LGNZZ Current Price and Quotes
0.0045
Previous Close
0.0045
Open
N/A

Daily Range
N/A - N/A
52wk Range
0.015 - 0.002

Volume
0
Dividend
N/A

Average Vol (3m)
4,233
Yield
N/A

Ligand Pharmaceuticals Incorporated LGNZZ
Company Information
11119 North Torrey Pines Road
Suite 200
La Jolla, CA 92037

Website: http://www.ligand.com
Phone: 858-550-7500

Ligand Pharmaceuticals Incorporated LGNZZ
Ligand discovers, develops and markets new drugs for critical unmet medical needs in the areas of cancer, pain, skin diseases, hormone-related diseases, osteoporosis, metabolic disorders, cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology related to intracellular receptors.

Ligand Pharmaceuticals Incorporated LGNZZ
Financial Reportings and Disclosures
Reporting Status U.S. Reporting: SEC Filer
Audited Financials Not Available
Latest Report Jun 30, 2013 10-Q
CIK 0000886163
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 1987
Employees 550 a/o Dec 31, 2004
Company Officers/Contacts
David E. Robinson President, CEO
Paul V. Maier CFO
Matthew W. Foehr EVP, COO
Charles S. Berkman Vice President, Secretary, General Counsel
Erika Luib IR
Company Directors
David E. Robinson Chairman
John LaMattina
Sunil Patel
Service Providers
Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available

Ligand Pharmaceuticals Incorporated LGNZZ
LGNZZ Security Details Other Company Securities
Share Structure
Market Value1 Not Available
Shares Outstanding Not Available
Float Not Available
Authorized Shares Not Available
Par Value No Par Value
Shareholders
Shareholders of Record Not Available
Short Selling Data
Short Interest 0 (-100%)
Jun 30, 2011
Significant Failures to Deliver No
Transfer Agent(s)

Ligand Pharmaceuticals Incorporated LGNZZ Recent News

Aug 14, 2013 Ligand Enters Global License Agreement with CURx Pharmaceuticals, Inc. for Captisol-Enabled(TM) Topiramate Injection
Aug 1, 2013 Ligand Reports Second Quarter Financial Results
Jul 29, 2013 New License Agreements and Financial Results Release - Research Report on Elan, Waters, InterMune, Spectranetics, and Ligand
Jul 26, 2013 Ligand Partner GlaxoSmithKline Receives Positive CHMP Opinion for REVOLADE(TM) in Thrombocytopenia Associated with Chronic Hepatitis C Infection
Jul 26, 2013 Ligand Receives Orphan Designation for Captisol-Enabled(TM) Topiramate Injection
Jul 24, 2013 Ligand Signs License Agreement with Ethicor for Oral Lasofoxifene
Jul 22, 2013 Ligand Signs Global License Agreement with Azure for Lasofoxifene
Jul 17, 2013 Ligand to Report Second Quarter Results on August 1st
Jun 24, 2013 Ligand Announces Positive Preclinical Data for Glucagon Program in Model of Type 1 Diabetes
Jun 20, 2013 Ligand Raises Ownership Limit for BVF Partners to 25% of Shares Outstanding

Ligand Pharmaceuticals Incorporated LGNZZ Financials
Period Ending Dec 31, 2012 Dec 31, 2011 Dec 31, 2010 Dec 31, 2009
Total Revenue 31,388 30,037 23,538 38,940
Cost of Revenue 3,601 4,909 - -
Gross Profit 27,787 25,128 23,538 38,940
Operating Expenses
Research and Development 10,790 10,291 22,067 39,870
Sales, General and Admin. 16,108 13,275 11,127 (6,640)
Non-Recurring Items 315 2,260 19,648 15,677
Other - - - -
Operating Income 574 (698) (29,304) (9,967)
Income From Continuing Operations
Add'l Income/Expense Items (1,134) (383) 13,519 365
Earnings Before Interest and Tax (3,865) (3,558) (15,403) (9,602)
Interest Expense - - - 270
Earnings Before Tax (3,865) (3,558) (15,403) (9,872)
Income Tax (1,191) (13,270) (2,617) (1,535)
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (2,674) 9,712 (12,786) (8,337)
Non Recurring Events
Discontinued Operations 2,147 3 2,413 6,389
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (527) 9,715 (10,373) (1,948)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (527) 9,715 (10,373) (1,948)

LGNZZ Ligand Pharmaceuticals Incorporated Research DD Guide

LGNZZ Ligand Pharmaceuticals Incorporated Stock Message Board http://investorshangout.com/search?q=LGNZZ&am...mp;yt0=Go!
LGNZZ Ligand Pharmaceuticals Incorporated Stock Quote http://www.otcmarkets.com/stock/LGNZZ/quote
LGNZZ Ligand Pharmaceuticals Incorporated Stock Chart http://www.otcmarkets.com/stock/LGNZZ/chart
LGNZZ Ligand Pharmaceuticals Incorporated Company Info http://www.otcmarkets.com/stock/LGNZZ/company-info
LGNZZ Ligand Pharmaceuticals Incorporated Recent News http://www.otcmarkets.com/stock/LGNZZ/news
LGNZZ Ligand Pharmaceuticals Incorporated Financials http://www.otcmarkets.com/stock/LGNZZ/financials
LGNZZ Ligand Pharmaceuticals Incorporated Filings and Disclosure http://www.otcmarkets.com/stock/LGNZZ/filings
LGNZZ Ligand Pharmaceuticals Incorporated Short Sales http://www.otcmarkets.com/stock/LGNZZ/short-sales
LGNZZ Ligand Pharmaceuticals Incorporated Insider Disclosure http://www.otcmarkets.com/stock/LGNZZ/insider-transactions
LGNZZ Ligand Pharmaceuticals Incorporated Research Reports http://www.otcmarkets.com/stock/LGNZZ/research
LGNZZ Ligand Pharmaceuticals Incorporated Summary http://finance.yahoo.com/q?s=LGNZZ
LGNZZ Ligand Pharmaceuticals Incorporated Historical Prices http://finance.yahoo.com/q/hp?s=LGNZZ+Historical+Prices
LGNZZ Ligand Pharmaceuticals Incorporated Interactive Chart http://finance.yahoo.com/echarts?s=LGNZZ
LGNZZ Ligand Pharmaceuticals Incorporated Basic Chart http://finance.yahoo.com/q/bc?s=LGNZZ+Basic+Chart
LGNZZ Ligand Pharmaceuticals Incorporated Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=LGNZZ+Basic+Tech.+Analysis
LGNZZ Ligand Pharmaceuticals Incorporated Headlines http://finance.yahoo.com/q/h?s=LGNZZ+Headlines
LGNZZ Ligand Pharmaceuticals Incorporated Press Releases http://finance.yahoo.com/q/p?s=LGNZZ+Press+Releases
LGNZZ Ligand Pharmaceuticals Incorporated Company Profile http://finance.yahoo.com/q/pr?s=LGNZZ+Profile
LGNZZ Ligand Pharmaceuticals Incorporated Key Statistics http://finance.yahoo.com/q/ks?s=LGNZZ+Key+Statistics
LGNZZ Ligand Pharmaceuticals Incorporated Industry http://finance.yahoo.com/q/in?s=LGNZZ+Industry
LGNZZ Ligand Pharmaceuticals Incorporated Major Holders http://finance.yahoo.com/q/mh?s=LGNZZ+Major+Holders
LGNZZ Ligand Pharmaceuticals Incorporated Insider Transactions http://finance.yahoo.com/q/it?s=LGNZZ+Insider+Transactions
LGNZZ Ligand Pharmaceuticals Incorporated Insider Roster http://finance.yahoo.com/q/ir?s=LGNZZ+Insider+Roster
LGNZZ Ligand Pharmaceuticals Incorporated Income Statement http://finance.yahoo.com/q/is?s=LGNZZ
LGNZZ Ligand Pharmaceuticals Incorporated Balance Sheet http://finance.yahoo.com/q/bs?s=LGNZZ
LGNZZ Ligand Pharmaceuticals Incorporated Cash Flow http://finance.yahoo.com/q/cf?s=LGNZZ+Cash+Flow&annual
LGNZZ Ligand Pharmaceuticals Incorporated Nasdaq http://www.nasdaq.com/symbol/LGNZZ
LGNZZ Ligand Pharmaceuticals Incorporated Market Watch http://www.marketwatch.com/investing/stock/LGNZZ
LGNZZ Ligand Pharmaceuticals Incorporated Bloomberg http://www.bloomberg.com/quote/LGNZZ:US
LGNZZ Ligand Pharmaceuticals Incorporated Morningstar http://quotes.morningstar.com/stock/s?t=LGNZZ
LGNZZ Ligand Pharmaceuticals Incorporated Bussinessweek http://investing.businessweek.com/research/st...cker=LGNZZ
LGNZZ Ligand Pharmaceuticals Incorporated Barchart http://www.barchart.com/quotes/stocks/LGNZZ
LGNZZ Ligand Pharmaceuticals Incorporated OTC Short Report http://otcshortreport.com/index.php?index=LGNZZ
LGNZZ Ligand Pharmaceuticals Incorporated Investopedia http://www.investopedia.com/markets/stocks/LGNZZ/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Honeywell Aerospace Faces Legal Turbulence in Fraud Case

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Home Buying: Unmasking All the Real Budget Costs

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...

Gourmia Introduces Ceramic-Coated Air Fryer at Costco

A New Era for Home Cooking with Gourmia Stepping into the kitchen appliances arena with a dash of innovation, Gourmia has launched its first ceramic-coated air fryer, and it’s weaving its way exclusively onto the shelves of Costco. Now, it’s not just about frying anymore; it’s about adding style, efficiency, and a touch of healthy living to your countertop. But much...

Truck Drivers USA & Career Driver Unveil New Driver Agent

Revolutionizing Driver-Carrier Connections In today's cranking transportation scene, Truck Drivers USA (TDUSA) and Career Driver have taken a bold step to change up the driver recruitment game. They've launched what's being labeled as the first 'driver agent' within the Career Driver mobile app. It's the talk of the town in Sherwood, Arkansas, these days. This isn't just...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Montesodi 2023: A Fresh Chapter in Chianti Excellence

A Glass Filled with History and Nature's Whimsy When you pour a glass of Montesodi 2023, you’re not just tasting wine but a story—a saga that blends Tuscany’s rich vineyard history with last year's unpredictable weather. Marchesi Frescobaldi, a name that’s seen it all over its thousand years, has once again shown us how resilience and tradition can marry with...

Canada and Ukraine Fortify Defense with UGV Partnership

New Defense Fronts: Canada and Ukraine Join Forces October 13, 2026, marks an important day in Ottawa's defense narrative with Dominion Dynamics and Ukraine's TENCORE kicking off a robust partnership. They're not just collaborating; they're plugging into each other's strengths to build TerMIT uncrewed ground vehicles (UGVs) on Canadian soil. These aren't gizmos you find...

A1 Refrigeration Keeps East Texas Homes Comfortable Year-Round

Homeowners in East Texas would agree: the last thing you want is your HVAC system throwing a tantrum when you're in the thick of a scorching summer or a biting winter. That's where A1 Refrigeration & Air Conditioning steps in, making sure folks in Jasper, Brookeland, and Kirbyville aren't left sweating bullets or shivering in their boots. Preventive Maintenance: A...

WIN Expands Leadership Amidst Rapid Growth Surge

Why WIN's Leadership Shake-Up Matters Change is afoot at the fertility and family support powerhouse WIN, and there's no mistaking the bold handwriting on the wall. As they swell towards supporting one million families, WIN's revamping their leadership table with three key players aimed at pushing the envelope further than before. They've got Claudio Stefan, Stacey...

Cogent Communications' Q3 2026 Earnings Call Details

Cue the Countdown: Cogent’s Earnings Call Looms Another quarter rolls by, and with it comes Cogent Communications' chance to strut—or stumble—before the crowd. Their third-quarter earnings call on November 5, 2026, is like the opening bell for a stock that's zipped through more ups and downs than a tired bullfighter's routine. What the call reveals on that crisp...